The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis
- Authors
- Yoo, Dae Hyun
- Issue Date
- Aug-2014
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- affordability; biosimilar; immunogenicity; infliximab; microheterogeneity; rheumatoid arthritis; switching
- Citation
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY, v.10, no.8, pp.981 - 983
- Indexed
- SCIE
SCOPUS
- Journal Title
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY
- Volume
- 10
- Number
- 8
- Start Page
- 981
- End Page
- 983
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159397
- DOI
- 10.1586/1744666X.2014.932690
- ISSN
- 1744-666X
- Abstract
- Although biologic agents are effective in the treatment of rheumatoid arthritis, the high price of drugs and restricted health care budgets have restricted easy access to biologics. Eventually, the use of biologic disease-modifying antirheumatic drugs might be inversely associated with disease activity in countries with low gross domestic product. The EMA approved an infliximab biosimilar for the first time in September 2013. The first approval of a biosimilar monoclonal antibody by a major regulatory authority provided a global standard for subsequent biosimilars and for biopharmaceutical companies developing biosimilars. Biosimilars with a highly similar quality and efficacy profile at an acceptable lower cost would significantly increase affordability of biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. Here, we will review the current status of first biosimilar antibody agent and the potential discussion points raised against biosimilars. In addition, the importance of awareness on biosimilars for stakeholders is discussed.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159397)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.